Product Overview

IVFhMG 75iu (Menotrophin [HMG]) is a sterile lyophilized powder supplied in a glass vial for reconstitution before injection. Each vial contains 75 international units of purified human menotropin, accompanied by a separate ampoule of 0.9% sodium chloride solution. The product is sealed in a tamper‑evident container and must be stored refrigerated at 2‑8 °C. Once reconstituted, the solution is used within 30 minutes to preserve potency. Administration can be performed subcutaneously or intramuscularly, providing flexibility for clinical settings.

What is IVFhMG 75iu (Menotrophin [HMG])?

The medication belongs to the class of gonadotropins, glycoprotein hormones that mimic the actions of endogenous follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). In women, IVFhMG binds to FSH receptors on ovarian granulosa cells, stimulating aromatase, leading to increased estradiol synthesis and follicular maturation. In men, it activates LH receptors on Leydig cells, promoting testosterone production. The recombinant formulation ensures consistent biological activity across batches, supporting predictable follicular development in assisted reproduction and reliable testosterone up‑regulation in hypogonadal men.

Uses and Benefits

IVFhMG 75iu is primarily used to induce controlled ovarian hyperstimulation in assisted reproductive technology cycles, increasing the number of mature oocytes available for retrieval. In male patients, the agent supports restoration of testosterone production, which can improve libido, muscle mass, and sperm parameters in cases of hypogonadism. Clinical studies have shown that appropriate dosing can raise clinical pregnancy rates by approximately 10‑15 % compared with unstimulated cycles in selected populations. Additionally, the therapy may be incorporated into fertility preservation protocols for oncology patients, where hormonal optimization precedes gamete cryopreservation.

How It Works

The medication functions by delivering follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity after reconstitution. In women, binding to FSH receptors on granulosa cells stimulates aromatase, leading to increased estradiol synthesis and follicular maturation. In men, LH receptor activation on Leydig cells enhances intracellular cAMP signaling, driving testosterone production. The dual‑hormone effect synchronizes ovarian development and endometrial receptivity, creating an environment favorable for embryo implantation. Molecularly, the recombinant protein engages intracellular pathways involving cyclic AMP and protein kinase A, ensuring consistent biological potency.

Clinical Evidence and Success Rates

Numerous clinical trials have evaluated the efficacy of menotropin in controlled ovarian stimulation, reporting live birth rates of 30‑35 % per transfer in favorable cohorts when combined with embryo transfer protocols. Meta‑analyses indicate that menotropin yields a comparable or slightly higher oocyte yield than urinary gonadotropins, with a similar safety profile. In male hypogonadism, long‑term studies demonstrate a mean increase in serum testosterone of 3‑5 ng/mL after 12 weeks of therapy, accompanied by improvements in lean body mass and sperm concentration in approximately 40 % of participants. These data are published in peer‑reviewed journals and are accessible through databases such as PubMed and the National Institutes of Health’s clinical trials registry. Regulatory oversight is provided by the U.S. Food and Drug Administration (FDA).

Dosage Guidelines

Dosage is individualized based on age, ovarian reserve, and prior response. A typical starting regimen consists of a single 75iu injection daily for up to 12 days, with dose adjustments guided by ultrasound monitoring of follicular growth. If fewer than three follicles reach 18 mm, the dose may be reduced or the cycle canceled to lower the risk of ovarian hyperstimulation syndrome. In men, the usual schedule is 75iu administered every 48 hours for several weeks, with serum testosterone measured to guide titration. Missed doses should not be doubled; instead, the next scheduled injection proceeds as planned. Reconstitution must be performed with the provided sterile sodium chloride, and the solution used within 30 minutes of preparation. Follow‑up monitoring typically includes serum hormone assessments on day 6 and day 9, with additional ultrasounds on days 6‑8 and thereafter every 24 hours until lead follicles reach maturity. If serum estradiol exceeds 3,000 pg/mL, clinicians may consider dose reduction to prevent excessive response. In male patients, testosterone levels are checked at baseline, after four weeks, and then every eight weeks to ensure therapeutic range maintenance. Documentation of all measurements should be retained for regulatory compliance.

Side Effects

Most adverse events are mild and include redness, swelling, or pain at the injection site. Headache, abdominal discomfort, and transient nausea have been reported in a small proportion of patients. The most serious concern is ovarian hyperstimulation syndrome (OHSS), which occurs in less than 2 % of cycles and may present with rapid weight gain, ovarian enlargement, and shortness of breath; management involves discontinuation of therapy and close monitoring of fluid balance. Allergic reactions, though rare, can manifest as urticaria or anaphylaxis and require immediate medical attention. Long‑term safety data are still being collected, and clinicians are advised to schedule periodic follow‑up assessments to monitor endocrine function and overall health.

Warnings and Precautions

IVFhMG 75iu is contraindicated in patients with known hypersensitivity to gonadotropins or any component of the formulation. Caution is recommended in individuals with ovarian cysts, unexplained vaginal bleeding, or a history of thromboembolic disease. Prior to initiation, a complete hormonal evaluation and pelvic ultrasound are advised to assess ovarian morphology and endometrial thickness. The product should not be used during pregnancy or while breastfeeding. Storage requires refrigeration at 2‑8 °C, and once reconstituted the solution must be administered within 30 minutes to maintain efficacy. Concomitant use of anticoagulants or hormone‑modulating agents may necessitate additional monitoring, and baseline liver function tests are recommended for safety. The medication is regulated by the U.S. Food and Drug Administration (FDA).

Frequently Asked Questions

1. What condition does IVFhMG 75iu treat? It is indicated for female infertility associated with ovulatory dysfunction and for male hypogonadism resulting in low testosterone levels.
2. How is the medication administered? After reconstitution with the supplied sterile sodium chloride, the solution is injected subcutaneously or intramuscularly as directed by the prescribing clinician.
3. Can IVFhMG be used for polycystic ovary syndrome (PCOS)? Yes, when ovulation induction is required, clinicians may employ this gonadotropin to stimulate follicular development in women with PCOS.
4. Is there a risk of multiple pregnancies? Gonadotropin therapy can increase the chance of multiple gestations; careful ultrasound monitoring helps mitigate this risk.
5. Where can I obtain IVFhMG 75iu? The product is available through licensed pharmacies and authorized online retailers that comply with regulatory standards.

Patients are encouraged to discuss any questions with their fertility specialist before starting therapy. Regular follow‑up visits enable dose adjustments, monitoring of treatment response, and early detection of adverse effects. When purchasing IVFhMG 75iu, select a licensed pharmacy that adheres to national regulatory guidelines to ensure product authenticity and safety. Adherence to prescribed protocols enhances the likelihood of achieving desired reproductive outcomes.

Related Products

• Emepitant (Aprepitant)
• Menotropin HMG 150iu Injection (Generic)
• Menotropin HMG 75iu Injection (Generic)
• IVFhMG 150iu (Menotrophin [HMG])
• hMG 1200iu Injection (Menotrophin)
• hMG 150iu Injection (Menotrophin)
• hMG 75iu Injection (Menotrophin)
• ZyHMG 75iu Injection (Menotrophin [HMG])
• ZyHMG 150iu Injection (Menotrophin (HMG))
• IVFhCG 5000 (HCG (Human Chorionic Gonadotropin))
• IVFhCG 1500iu (HCG (Human Chorionic Gonadotropin))
• Human Chorionic Gonadotropin 1500iu (Generic)